Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

Common Warts Clinical Trial

Official title:
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years

Status Active, not recruiting

Clinical Trial Summary

Warts are benign epidermal tumors caused by human papillomaviruses (HPVs). The active pharmaceutical ingredient DPCP has been used for many years as a compounded formulation in acetone for the treatment of warts, alopecia areata and more recently, cutaneous metastatic melanoma lesions. An improved topical ointment formulation of DPCP called Samcyprone™ will be evaluated for the treatment of common warts.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02640820
Study type	Interventional
Source	RXi Pharmaceuticals, Corp.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	December 2015
Completion date	May 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01286441` - A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts	Phase 2
Completed	`NCT02798419` - Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts	Phase 2
Completed	`NCT02669862` - A Study of A-101 Solution in Subjects With Common Warts.	Phase 2
Completed	`NCT02650466` - Nanopulse Efficacy Study for the Treatment of Common Warts	N/A
Not yet recruiting	`NCT03166137` - Carbon Dioxide Laser and Cryotherapy in Treatment of Warts	N/A
Completed	`NCT02748902` - Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.	Phase 1